Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04937319 once-daily · 1 trial · 1 indication
Plasma glucose concentration was determined predose (Hour 0) and at 1.5, 3, 5, 6.5, 8, 11, 12.5, 14, 16, 20, and 24 hours postdose on Days 0 (baseline) and 14. WMDG was calculated as the area under the curve (AUC) of the 12-point plasma glucose concentration-time profile divided by 24 hours.
| Arm | Type | Description |
|---|---|---|
| PF-04937319 once-daily | EXPERIMENTAL | - |
| PF-04937319 split-dose | EXPERIMENTAL | - |
| Sitagliptin once-daily | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04937319 once-daily | DRUG | Tablets, 300 mg once-daily with breakfast, 14-days |
| PF-04937319 split-dose | DRUG | tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days |
| Sitagliptin once-daily | DRUG | tablets, 100 mg once-daily with breakfast, 14-days |
Inclusion Criteria: * Patients with type 2 diabetes, on background metformin therapy either alone or with 1 other oral anti-diabetic agent (excluding Actos) Exclusion Criteria: * Patients with cardiovascular event within 6-months of screening * Patients with diabetic complications * Female subjec...
PF-04937319 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The molecular target of PF-04937319 has not been disclosed in available information. It is being studied as a potential treatment for Type 2 Diabetes Mellitus, but its specific mechanism of action is not publicly detailed.
PF-04937319 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE.
PF-04937319 is in Phase 1 clinical development. It is an investigational drug and has not yet received approval from regulatory agencies for the treatment of Type 2 Diabetes Mellitus.
PF-04937319 has been studied in one completed clinical trial, NCT01933672, which evaluated two dosing regimens of the drug compared to sitagliptin in patients with Type 2 Diabetes Mellitus. The trial enrolled 33 participants in the United States.
No, PF-04937319 is not the same as sitagliptin. Sitagliptin is an approved agent used as an active comparator in the clinical trial of PF-04937319, which is an investigational drug being studied for Type 2 Diabetes Mellitus.